AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Wet AMD

AsclepiX Therapeutics announced the completion of enrollment into the DISCOVER trial (NCT05859776) evaluating the safety and tolerability of three dose strengths of AXT107 (gersizangitide) for wet AMD. In the trial, 15 patients will receive either 125 µg (n=3), 250 µg (n=3), or 500 µg (n=9) of AXT107, which will evaluate the safety and tolerability, as well as determine the bioactivity and duration of action when injected suprachoroidally. Secondary endpoints will include efficacy as assessed by central subfield thickness (CST) and best-corrected visual acuity (BCVA). Following a single injection of AXT107, to date, no patient has shown any remarkable safety findings.

“I would like to thank the team and sites for their unwavering commitment, collaborative spirit, and meticulous execution they brought to the enrollment of the DISCOVER trial,” Robert J. Dempsey, Chief Executive Officer, AsclepiX Therapeutics, said in a company news release. “Rapid enrollment was a tribute to the partnership of our principal investigators, Drs. David Almeida, William Bridges, Sabin Dang, and David Lally, who played a critical role in achieving this significant milestone for patients.”

AsclepiX’s lead clinical candidate, integrin regulating peptide AXT107, has a novel mechanism of action that inhibits neovascularization, reduces vascular permeability, and suppresses vascular inflammation. Given as a microparticulate suspension suitable for suprachoroidal injection, AXT107 is designed to maintain sustained biological activity with one injection well beyond the current standard of care.